Skip to main content
. 2018 Oct 24;13(10):e0206261. doi: 10.1371/journal.pone.0206261

Fig 3. Kaplan–Meier analysis of cumulative 5-year overall survival (OS) in relation to the number of presented markers in HCC patients.

Fig 3

(A) Patients with HCCs who were positive for both H3K36me3 and CK19 expression exhibited the lowest 5-year OS, significantly lower than that of patients with HCCs with either H3K36me3 positivity or CK19 expression (P = 0.0027), whereas patients with HCCs without H3K36me3 positivity or CK19 expression had the highest 5-year OS (P = 0.0001). (B) Patients with HCCs who were positive for both H3K36me3 and HNF1β expression had the lowest 5-year OS, marginally lower than those with HCCs with either H3K36me3 positivity or HNF1β expression (P = 0.0530), whereas patients with HCCs without H3K36me3 positivity or HNF1β expression had the highest 5-year OS (P = 0.0038). (C) Cumulative survival in relation to the number of presented markers (H3K36me3, CK19, and HNF1β). Patients presenting more markers were more likely to exhibit lower 5-year OS (P = 0.0008); however, the differences in survival of patients with HCC positive for two or three markers were nonsignificant. N, number of markers present.